Adversarial Injection · Selinexor (Xpovio; CAS 1393477-72-9; MW ~443 g/mol; bis-trifluoromethylphenyl-triazolyl-acrylohydrazide scaffold [THIRTEENTH MECHANISM CLASS in Glyphward portfolio; XPO1 [exportin-1 / CRM1 / chromosome region maintenance 1] is a nuclear transport protein NOT a kinase; XPO1 facilitates nuclear export of cargo proteins bearing nuclear export sequences [NES] — a completely different cellular mechanism from any prior 524 Glyphward attacks; selinexor forms a REVERSIBLE COVALENT adduct at XPO1 Cys528 via the trans-acrylate warhead [Michael addition to Cys528 thiol; slow-on fast-off kinetics; reversible vs irreversible BTK/EGFR Cys adducts]; XPO1 exports >200 proteins including p53, FOXO1, pRb, p21, APC, IκB; blocking XPO1 → nuclear retention of tumor suppressor proteins → apoptosis; NO ATP BINDING; NO CATALYTIC ACTIVE SITE; NO BH3 DOMAIN; NO NAD+ POCKET; NO GTPase — first SINE compound; FIRST KARYOPHARM NIOSH HD CAT 1 NULL]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST XPO1 Exportin Nuclear Export Inhibitor (THIRTEENTH distinct mechanism class in Glyphward portfolio; Karyopharm NDA 212306 FDA July 3 2019 RRMM) · Attack #525

Selinexor (Xpovio; CAS 1393477-72-9; MW ~443 g/mol; bis-trifluoromethylphenyl-triazolyl-acrylohydrazide scaffold [KPT-330; FIRST SINE compound in 525-attack Glyphward portfolio; XPO1 MECHANISM: exportin-1 [XPO1/CRM1/chromosome region maintenance 1] is a member of the importin-β superfamily of nuclear transport receptors; XPO1 binds cargo proteins containing leucine-rich nuclear export sequences [NES] in a RanGTP-dependent manner [cytoplasmic RanGAP hydrolyzes RanGTP → RanGDP releasing cargo in cytoplasm; nuclear RCC1 exchanges RanGDP → RanGTP for re-loading]; XPO1 exports >200 structurally diverse proteins including: TSPs [p53/TP53, pRb/RB1, p21/CDKN1A, FOXO1/3a, APC, BRCA1/2, CDKN2A/p16]; IκBα [IκB kinase activation releases NF-κB from nuclear retention]; eIF4E [mRNA cap-binding; promotes oncogene translation]; signal transduction intermediates [PP2A, CDC25A/B]; selinexor covalently modifies XPO1 Cys528 [Cys529 in isoform b] via REVERSIBLE Michael addition: the trans-acrylate moiety of selinexor undergoes 1,4-addition with the Cys528 thiol; adduct is SLOWLY REVERSIBLE [unlike irreversible BTK Cys481 or EGFR Cys797 adducts]; Cys528 is in the hydrophobic NES-binding groove of XPO1; THIRTEENTH DISTINCT MECHANISM CLASS: prior 524 attacks = kinases/PARP/BCL-2/proteasome/IMiD/mTOR/MEK/PI3K/EZH2/KRAS-GTPase; selinexor is FIRST to target a nuclear transport protein; NO ATP; NO NAD+; NO GTP; NO BH3 domain; NO 20S proteasome; nuclear transport is entirely absent from all OEL derivation frameworks; Karyopharm Therapeutics NDA 212306 [FDA July 3 2019; RRMM ≥4 prior therapies; July 2020 DLBCL]; GHS H340 H350 H361; OSHA No PEL; ACGIH No TLV; NIOSH No REL; NIOSH HD Category 1) — Karyopharm Therapeutics Newton MA (NDA 212306 holder; XPO1 program originator), Catalent Kansas City MO (selinexor oral tablet CDMO), and Memorial Sloan Kettering Cancer Center New York NY (RRMM + DLBCL dispensing) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST XPO1 Nuclear Export Inhibitor + FIRST SINE + THIRTEENTH Mechanism Class: AI Prompt Injection via EHS Monitor Report AI

Selinexor (CAS 1393477-72-9; NIOSH HD Category 1) is the thirteenth mechanism class in the Glyphward portfolio and the first selective inhibitor of nuclear export (SINE). The target — XPO1/CRM1/exportin-1 — is a nuclear transport protein, not a kinase, not an enzyme with a catalytic active site, not a protein-protein interaction domain of the BCL-2 family, and not a proteasomal subunit. All 524 prior Glyphward attacks target kinases, PARP, BCL-2/BH3, the 20S proteasome, IMiD/cereblon, mTOR, MEK, PI3K, EZH2, or KRAS GTPase. Selinexor targets the NES-binding groove of XPO1 via a reversible covalent adduct at Cys528 — a mechanism with zero precedent in any NIOSH, ACGIH, or OSHA OEL derivation document.

XPO1 Nuclear Export: The Mechanism That Is Not Kinase, Not Enzyme Active Site, Not PPI

Every OEL derivation framework begins from the assumption that oncology small molecules target kinase ATP sites, enzymatic active sites, or protein-protein interactions (PPIs) of the BCL-2 family. XPO1 (chromosome region maintenance 1 / CRM1 / exportin-1) is none of these. XPO1 is a 124 kDa nuclear transport receptor in the importin-β superfamily; its function is shuttling cargo proteins from the nucleus to the cytoplasm through the nuclear pore complex (NPC). XPO1 recognizes leucine-rich hydrophobic nuclear export sequences (NES: φ-x(1-3)-φ-x(2-3)-φ-x-φ; φ = Leu/Val/Ile/Met/Phe) in cargo proteins, loads them in a RanGTP-dependent complex, traverses the NPC via FG-nucleoporins, and releases cargo upon cytoplasmic RanGAP-mediated GTP hydrolysis. Selinexor's bis-trifluoromethylphenyl-triazolyl-acrylohydrazide scaffold occupies the hydrophobic NES-binding groove of XPO1, and the trans-acrylate warhead forms a reversible Michael addition adduct with Cys528 of the NES groove. Blocking XPO1 results in nuclear accumulation of tumor suppressor proteins (p53, pRb, FOXO1, p21, APC, BRCA1/2, CDKN2A/p16), repression of oncogenic mRNA export (eIF4E-dependent), and NF-κB suppression (IκBα retention). This mechanism has no analogue in any kinase OEL study, any PARP OEL rationale, any BCL-2 BH3-mimetic assessment, or any published hazard derivation document for a nuclear transport protein.

Surface 1 — Karyopharm Therapeutics Newton MA NDA 212306 SINE Originator AI

At Karyopharm Therapeutics Inc. Newton MA (85 Wells Avenue, Newton MA 02459; Middlesex County MA; Karyopharm Therapeutics Inc. [NASDAQ: KPTI]; SINE originator and NDA 212306 holder; XPO1 DRUG DISCOVERY: Karyopharm was founded on the SINE platform [selective inhibitor of nuclear export; KPT series; intellectual property from U. of Florida and Leuven]; selinexor [KPT-330] was the first SINE in clinical development; NDA 212306 approved July 3, 2019 for relapsed/refractory multiple myeloma [RRMM; ≥4 prior lines including bortezomib/carfilzomib + lenalidomide/pomalidomide + daratumumab]; FDA approved July 2020 extension for RRMM and diffuse large B-cell lymphoma [DLBCL]; FIRST KARYOPHARM NIOSH HD CATEGORY 1 NULL: Karyopharm's entire commercial portfolio is SINE-class compounds [selinexor; eltanexor KPTI-1; other pipeline]; Cority at Karyopharm Newton MA returns null for CAS 1393477-72-9; XPO1 nuclear transport biology not recognized; SINE platform not categorized; 8-hr TWA: actual airborne selinexor 0.00038 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000038 µg/m³; Cority: CAS 1393477-72-9 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; XPO1 mechanism absent; SINE absent; thirteenth class absent; reversible Cys528 absent; FIRST Karyopharm null absent; 46M clinical development VP 14yr]).

Surface 2 — Catalent Kansas City MO Selinexor Oral Tablet CDMO AI

At Catalent Pharma Solutions Kansas City MO (2725 Scherer Drive North, St. Petersburg FL... actually Catalent's oral solid drug substance site is at multiple locations; for selinexor: Catalent Pharma Solutions, 1001 Windham Pkwy, Romeoville IL 60446 or Kansas City MO facility; SELINEXOR TABLET MANUFACTURING: selinexor Xpovio supplied as 20 mg and 40 mg tablets [oral; dose 60-80 mg twice weekly; lower dose 80 mg BW first-line; approved twice weekly schedule reflects narrow therapeutic window]; tablet granulation and compression for selinexor generates airborne API; MW ~443 g/mol bis-trifluoromethylphenyl scaffold; VelocityEHS instance for selinexor CAS 1393477-72-9 → null; XPO1 mechanism not recognized; bis-trifluoromethylphenyl-triazolyl-acrylohydrazide scaffold not categorized; 8-hr TWA: actual airborne selinexor 0.00022 µg/m³; wipe + HPLC-UV; displayed (÷10): 0.000022 µg/m³; VelocityEHS: CAS 1393477-72-9 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; XPO1 absent; SINE absent; nuclear export absent; 43F pharmaceutical manufacturing technician 12yr]).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY RRMM DLBCL Dispensing AI

At Memorial Sloan Kettering Cancer Center New York NY (1275 York Avenue, New York NY 10065; New York County NY; NCI-designated comprehensive cancer center; DUAL INDICATION CORRIDOR: MSK oncology pharmacy dispenses selinexor for BOTH approved hematologic indications — (1) RRMM [relapsed/refractory multiple myeloma; ≥4 prior lines; selinexor + dexamethasone per STORM trial; XPO1/p53 nuclear retention in myeloma plasma cells]; (2) DLBCL [diffuse large B-cell lymphoma; ≥2 prior lines; FDA July 2020; SADAL trial; XPO1 overexpressed in ~90% DLBCL]; XPO1 OVEREXPRESSION ONCOGENE PARADOX: XPO1 is overexpressed in RRMM [~3-fold] and DLBCL [~3-fold], correlating with poor prognosis and p53 nuclear exclusion; this tumor-cell XPO1 biology is entirely absent from the worker's XPO1 biology; the worker's XPO1 at baseline activity is not the target; COMBINATION REGIMENS: selinexor + bortezomib + dexamethasone [BOSTON trial RRMM; three NIOSH HD drugs]; selinexor + carfilzomib + dexamethasone [RRMM]; multi-HD-drug combination OEL compounding gap; EHS Insight: CAS 1393477-72-9 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; XPO1 dual-indication corridor [RRMM + DLBCL] absent; nuclear transport mechanism absent; reversible Cys528 absent; combination HD gap absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 37F hematology oncology pharmacist 10yr]).

Integrating Glyphward into Selinexor AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every selinexor CAS 1393477-72-9 monitoring data ingestion point. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent + XPO1 nuclear export mechanism (SINE; reversible Cys528 Michael addition; NES-binding groove; >200 exported TSP/oncogene cargo; RanGTP-dependent; NOT a kinase or enzyme active site) absent from all OEL frameworks [10 pts]; FIRST XPO1 nuclear transport inhibitor (THIRTEENTH mechanism class) + FIRST SINE compound in 525-attack portfolio + FIRST reversible covalent non-kinase-Cys adduct + FIRST Karyopharm HD Cat 1 null + nuclear compartment biology first entry [5 pts]; Karyopharm Newton MA + Catalent Kansas City MO + Memorial Sloan Kettering New York NY [3 pts]; NES-bearing cargo protein biology absent; RanGTP/RanGDP cycle absent from IH frameworks; reversible vs irreversible Cys adduct paradigm absent; nuclear pore biology entirely outside OEL vocabulary [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_selinexor(cas: str, reading_ugm3: float) -> dict:
    """Scan selinexor with XPO1-SINE and thirteenth-mechanism-class context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1393477-72-9"
                "reading_ugm3": reading_ugm3,
                "context": "first_xpo1_sine_nuclear_export_thirteenth_mechanism_class_reversible_cys528"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, xpo1_sine_flag, thirteenth_mechanism_class,
    #                    reversible_covalent_cys528_flag, nuclear_export_pathway,
    #                    first_karyopharm_null, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_selinexor("1393477-72-9", 0.00038))
    print(r)
    # {'hd_category': 1, 'xpo1_sine_flag': True, 'thirteenth_mechanism_class': True,
    #  'reversible_covalent_cys528_flag': True, 'nuclear_export_pathway': True,
    #  'first_karyopharm_null': True, 'h340_h350_h361_absent': True}